Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
2019; Massachusetts Medical Society; Volume: 380; Issue: 12 Linguagem: Inglês
10.1056/nejmoa1816047
ISSN1533-4406
AutoresRobert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Négrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, B. Yа. Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Hariharan Subramanian, Bo Huang, Alessandra di Pietro, Toni K. Choueiri,
Tópico(s)Economic and Financial Impacts of Cancer
ResumoIn a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses in patients with advanced renal-cell carcinoma. This phase 3 trial involving previously untreated patients with advanced renal-cell carcinoma compared avelumab plus axitinib with the standard-of-care sunitinib.
Referência(s)